Multiple Myeloma

Sham Mailankody, MBBS, discusses minimal residual disease negativity in multiple myeloma.

Ajai Chari, MD, discusses transplant eligibility in multiple myeloma.

Alfred L. Garfall, MD, provides insight on the FDA approval of daratumumab added to bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

The European Commission has approved the triplet regimen of daratumumab with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Marc J. Braunstein, MD, PhD, discusses the ultra–high-risk patient population in smoldering multiple myeloma.

Sagar Lonial, MD, FACP, discusses treatments for patients with heavily pretreated multiple myeloma.

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses methods of evaluating measurable residual disease (MRD) in multiple myeloma.

Ajay K. Nooka, MD, MPH, FACP, discusses current options for transplant-eligible and -ineligible patients with multiple myeloma.

We sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.

Imaging approaches and technologies have advanced dramatically since the last such guidance was developed a decade ago, driving earlier and more effective detection and treatment.

Ivan M. Borrello, MD, discusses treatment for patients with indolent versus aggressive relapsed multiple myeloma.

Sagar Lonial, MD, FACP, discusses the management of patients with relapsed multiple myeloma.

Ixazomib significantly improved progression-free survival as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.

Adam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.

Anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, have the potential to revolutionize the multiple myeloma treatment paradigm. At the 37 Annual CFS®, Sham Mailankody, MBBS, discussed the emerging BCMA-directed therapies that have shown the greatest potential.

Sham Mailankody, MBBS, discusses results of the CASSIOPEIA trial in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

Imad Tabbara, MD, discusses available treatment options for transplant-eligible and -ineligible patients with multiple myeloma.

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses the rationale for the posthoc analysis of the phase III ARROW study in multiple myeloma.

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

The FDA has granted a Regenerative Medicine Advanced Therapy designation to the investigational anti-BCMA CAR T-cell therapy CT053 for the treatment of patients with relapsed/refractory multiple myeloma.

Shaji K. Kumar, MD, discusses the takeaways from the phase III BELLINI trial which tested venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Ivan M. Borrello, MD, discusses the current multiple myeloma treatment paradigm.

Simon J. Harrison, MBBS, PhD, discusses the impact subcutaneous formulations of daratumumab and isatuximab could have in multiple myeloma.